1,2 The 2011 IOM report, Clinical Practice Guidelines We Can Trust, has added more urgency to improve the overall quality of clinical practice guidelines. 3 Increased reliance on evidence syntheses and use of relatively standardized structured approaches to guide decision making has improved the scientific rigor of guideline development. Despite these advancements, guideline developers still face many challenges. In the current environment of health care reform, one challenge is how guidelines can help define and promote high-value care and inform the development and establishment of meaningful performance measures focused on improving population health. The evidence assessment process requires further advancements to become more streamlined and efficient while still meeting currently acceptable standards.
In the United States, improving the quality of care has become a national priority with increasing emphasis on providing high-value care to patients. The new Medicare Access and CHIP Reauthorization Act signed into effect in April 2016 combines incentive payments with performance scores based on high-(or low-) value care services. 4 Prior performance measure-based incentive payment systems have been criticized for being based on guidelines that are not methodologically rigorous, lack transparency, or do not account for patients' values and preferences. 5 However, at least 2 major initiatives have gained momentum: (1) the American College of Physicians' (ACPs') High Value Care initiative and (2) the GRADE evidence-to-decision (EtD) framework. ACPs' High Value Care initiative outlines a standardized approach to help clinicians determine what screening, diagnosis, and treatment options are considered highvalue care. Clinical recommendations are developed for interventions identified as high value, which includes an evaluation of their benefits, harms, and costs. 6 The GRADE EtD framework presents a standardized approach to decision making for guideline developers. This framework weighs the certainty of the evidence, balance of benefits and harms, values and preferences, resource use, acceptability, equity, and feasibility to guide recommendation development and inform health care providers, policy makers, and the public. 7 During an Agency for Healthcare Research and Quality-funded meeting in 2012, public and private payers responded favorably to a version of the GRADE EtD framework, recognizing it as a framework to aid in policy decisions. 8 Continued US-based application and evaluation of ACPs' High Value Care initiative and the GRADE EtD framework will advance clinical guidelines to focus on highvalue care practice by incorporating cost data and patients' values and preferences in decision making, as well as inform performance measures.
An additional challenge are the resources required to perform a rigorous evidence assessment. Systematic reviews remain a time-intensive and expensive task; however, the Guidelines International Network and Academy of Medicine state that guidelines should be informed by systematic literature review. 3, 9 Several strategies are available to streamline the review process or guide the process of rapid reviews. Use of text-mining approaches to screen abstracts and software for data extraction are options to synthesize evidence faster for decision makers.
10 Rapid reviews, either integrating new publications into pooled analyses or qualitatively describing the consistency of their results, facilitating faster decision making, and automation of systematic reviews are promising for areas needing research and development.
In summary, we propose the following timely goals for the US guideline community to prioritize and address.
1. Guideline developers and organizations that create performance measures need to collaborate to define performance measures that are based on strong recommendations and a rigorous evidence assessment. 2. Guideline developers must strive to incorporate costs when evaluating benefits and harms of an intervention and use standardized tools, such as the GRADE EtD framework. 3. Guideline developers should advance methods to streamline systematic reviews or develop rapid reviews while maintaining quality and transparency.
